Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals

Abstract

OCA may represent the first pharmacological treatment approved for NASH. However, pruritis, constipation, diarrhea, and hyperlipidemia were major events with evident dose-dependent effect that affect tolerability in NASH. Future long-term studies for longitudinal safety events are required.